Chinese General Practice ›› 2024, Vol. 27 ›› Issue (12): 1493-1503.DOI: 10.12114/j.issn.1007-9572.2023.0390
• Original Research • Previous Articles Next Articles
Received:
2023-06-13
Revised:
2023-09-11
Published:
2024-04-20
Online:
2024-01-23
Contact:
DIAO He
通讯作者:
刁翯
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0390
Mol-ID | 化合物 | 靶蛋白个数(个) | OB(%) | DL | 药物来源 | 编号 |
---|---|---|---|---|---|---|
MOL000098 | 槲皮素(quercetin) | 149 | 46.43 | 0.28 | 丹皮、柴胡 | A1 |
MOL000422 | 山柰酚(kaempferol) | 61 | 41.88 | 0.24 | 丹皮、柴胡 | A2 |
MOL000359 | β-谷甾醇(β-sitosterol) | 38 | 36.91 | 0.75 | 柴胡、丹皮、山茱萸、泽泻 | B1 |
MOL000449 | 豆甾醇(Stigmasterol) | 31 | 43.83 | 0.76 | 柴胡、熟地、山药、山茱萸 | C1 |
Table 1 Active ingredients of Zuoci pill traditional Chinese medicine
Mol-ID | 化合物 | 靶蛋白个数(个) | OB(%) | DL | 药物来源 | 编号 |
---|---|---|---|---|---|---|
MOL000098 | 槲皮素(quercetin) | 149 | 46.43 | 0.28 | 丹皮、柴胡 | A1 |
MOL000422 | 山柰酚(kaempferol) | 61 | 41.88 | 0.24 | 丹皮、柴胡 | A2 |
MOL000359 | β-谷甾醇(β-sitosterol) | 38 | 36.91 | 0.75 | 柴胡、丹皮、山茱萸、泽泻 | B1 |
MOL000449 | 豆甾醇(Stigmasterol) | 31 | 43.83 | 0.76 | 柴胡、熟地、山药、山茱萸 | C1 |
序号 | 编号 | Mol-ID | 化合物 | 所属中药 | 中心度值 | 紧密中心度值 | 节点连接度值 |
---|---|---|---|---|---|---|---|
1 | A1 | MOL000098 | 槲皮素(quercetin) | 柴胡、丹皮 | 0.644 182 212 | 0.549 597 855 | 236 |
2 | A2 | MOL000422 | 山柰酚(kaempferol) | 柴胡、丹皮 | 0.122 348 153 | 0.405 940 594 | 86 |
3 | C1 | MOL000449 | 豆甾醇(stigmasterol) | 柴胡、山药、山茱萸、熟地 | 0.081 989 992 | 0.378 927 911 | 60 |
4 | B1 | MOL000359 | β-谷甾醇(beta-sitosterol) | 泽泻、丹皮、山茱萸、熟地 | 0.057 065 242 | 0.377 532 228 | 21 |
5 | CH4 | MOL000354 | 异鼠李素(isorhamnetin) | 柴胡 | 0.045 482 407 | 0.352 839 931 | 20 |
6 | SY10 | MOL000546 | 薯蓣皂苷(diosgenin) | 山药 | 0.080 706 371 | 0.370 705 244 | 17 |
7 | SZY10 | MOL008457 | 四氢鸭脚木碱(tetrahydroalstonine) | 山茱萸 | 0.034 819 519 | 0.359 019 264 | 16 |
8 | SY4 | MOL000322 | 海风藤酮(kadsurenone) | 山药 | 0.028 794 402 | 0.350 427 350 | 13 |
Table 2 Top 8 active ingredients in terms of network node connectivity value
序号 | 编号 | Mol-ID | 化合物 | 所属中药 | 中心度值 | 紧密中心度值 | 节点连接度值 |
---|---|---|---|---|---|---|---|
1 | A1 | MOL000098 | 槲皮素(quercetin) | 柴胡、丹皮 | 0.644 182 212 | 0.549 597 855 | 236 |
2 | A2 | MOL000422 | 山柰酚(kaempferol) | 柴胡、丹皮 | 0.122 348 153 | 0.405 940 594 | 86 |
3 | C1 | MOL000449 | 豆甾醇(stigmasterol) | 柴胡、山药、山茱萸、熟地 | 0.081 989 992 | 0.378 927 911 | 60 |
4 | B1 | MOL000359 | β-谷甾醇(beta-sitosterol) | 泽泻、丹皮、山茱萸、熟地 | 0.057 065 242 | 0.377 532 228 | 21 |
5 | CH4 | MOL000354 | 异鼠李素(isorhamnetin) | 柴胡 | 0.045 482 407 | 0.352 839 931 | 20 |
6 | SY10 | MOL000546 | 薯蓣皂苷(diosgenin) | 山药 | 0.080 706 371 | 0.370 705 244 | 17 |
7 | SZY10 | MOL008457 | 四氢鸭脚木碱(tetrahydroalstonine) | 山茱萸 | 0.034 819 519 | 0.359 019 264 | 16 |
8 | SY4 | MOL000322 | 海风藤酮(kadsurenone) | 山药 | 0.028 794 402 | 0.350 427 350 | 13 |
序号 | 靶基因 | 中心度值 | 紧密中心度值 | 节点连接度值 |
---|---|---|---|---|
1 | AKT1 | 0.059 715 47 | 0.780 104 71 | 107 |
2 | TP53 | 0.030 890 95 | 0.756 345 18 | 103 |
3 | IL-6 | 0.042 907 07 | 0.745 657 64 | 99 |
4 | VEGFA | 0.024 962 20 | 0.726 829 27 | 96 |
5 | CASP3 | 0.025 602 74 | 0.726 829 27 | 94 |
6 | IL-1β | 0.034 180 63 | 0.719 806 76 | 92 |
7 | EGFR | 0.034 828 92 | 0.716 346 15 | 90 |
8 | ESR1 | 0.040 838 92 | 0.712 918 66 | 90 |
9 | MYC | 0.033 866 46 | 0.702 830 19 | 89 |
10 | HIF1A | 0.009 612 23 | 0.680 365 30 | 84 |
Table 3 Top10 targets ranked by PPI network connectivity value
序号 | 靶基因 | 中心度值 | 紧密中心度值 | 节点连接度值 |
---|---|---|---|---|
1 | AKT1 | 0.059 715 47 | 0.780 104 71 | 107 |
2 | TP53 | 0.030 890 95 | 0.756 345 18 | 103 |
3 | IL-6 | 0.042 907 07 | 0.745 657 64 | 99 |
4 | VEGFA | 0.024 962 20 | 0.726 829 27 | 96 |
5 | CASP3 | 0.025 602 74 | 0.726 829 27 | 94 |
6 | IL-1β | 0.034 180 63 | 0.719 806 76 | 92 |
7 | EGFR | 0.034 828 92 | 0.716 346 15 | 90 |
8 | ESR1 | 0.040 838 92 | 0.712 918 66 | 90 |
9 | MYC | 0.033 866 46 | 0.702 830 19 | 89 |
10 | HIF1A | 0.009 612 23 | 0.680 365 30 | 84 |
组别 | 只数 | IL-1β | |
---|---|---|---|
SHAM组 | 20 | 29.58±5.66 | |
OVX组 | 20 | 39.65±8.35a | |
ZCW组 | 20 | 34.86±5.30ab | |
F值 | 11.73 | ||
P值 | <0.001 |
Table 4 Serum IL-1β level comparison among three groups
组别 | 只数 | IL-1β | |
---|---|---|---|
SHAM组 | 20 | 29.58±5.66 | |
OVX组 | 20 | 39.65±8.35a | |
ZCW组 | 20 | 34.86±5.30ab | |
F值 | 11.73 | ||
P值 | <0.001 |
[1] |
中华医学会妇产科学分会绝经学组. 中国绝经管理与绝经激素治疗指南2023版[J]. 中华妇产科杂志,2023,58(1):4-21. DOI:10.3760/cma.j.cn112141-20221118-00706.
|
[2] |
|
[3] |
|
[4] |
|
[5] |
刁翯,赵立东,白文佩. 雌激素对听力损失影响的研究进展[J]. 中国妇产科临床杂志,2019,20(4):382-384. DOI:10.13390/j.issn.1672-1861.2019.04.029.
|
[6] |
国家药典委员会. 中华人民共和国药典-一部:2020年版[M]. 北京:中国医药科技出版社,2020.
|
[7] |
严阿建,俞英英. 耳聋左慈丸联合声音疗法治疗肾精亏虚型慢性耳鸣临床研究[J]. 新中医,2023,55(3):151-154. DOI:10.13457/j.cnki.jncm.2023.03.033.
|
[8] | |
[9] |
游娇娇,裴秋萍,王小伟. 耳聋左慈丸对大鼠年龄相关性听力减退的干预作用及对耳蜗组织SOD、MDA水平的影响[J]. 内蒙古中医药,2023,42(1):126-128. DOI:10.16040/j.cnki.cn15-1101.2023.01.039.
|
[10] |
|
[11] |
叶坤,雷敏,谢欣,等. 基于网络药理学与分子对接技术探讨黄芪建中汤治疗腹泻型肠易激综合征的作用机制研究[J]. 中国全科医学,2022,25(15):1814-1824. DOI:10.12114/j.issn.1007-9572.2022.02.014.
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[22] |
|
[23] |
|
[24] |
|
[25] |
|
[26] |
|
[27] |
|
[28] |
|
[29] |
|
[30] |
|
[31] |
|
[32] |
|
[33] |
|
[34] |
|
[35] |
|
[36] |
|
[37] |
|
[38] |
|
[39] |
|
[1] | WANG Ruijie, LI Hongyu, SHI Hong. Association of Tooth Loss with Hearing Impairment in Chinese Older Adults Aged 65 Years and Above [J]. Chinese General Practice, 2024, 27(01): 45-50. |
[2] | ZHANG Kang, ZHAO Tingting, ZHANG Bo, GAO Mengqi, LI Yuxi, WANG Shaopeng, ZHAO Wenjing. Study on the Mechanism of Budesonide in the Treatment of IgA Nephropathy Based on Network Pharmacology [J]. Chinese General Practice, 2023, 26(35): 4453-4458. |
[3] | JIA Yu, ZHOU Zitong, CAO Xuehua, HU Wanqin, XIANG Feng, XIONG Langyu, WANG Xiaoxia. Incidence of Perimenopausal Syndrome in Chinese Women Aged 40 to 65 Years: a Meta-analysis [J]. Chinese General Practice, 2023, 26(32): 4080-4088. |
[4] | HE Jingyi, WANG Fang, SHUI Xiaoling, LI Ling, LIANG Qian. Efficacy of Non-pharmacological Interventions to Improve Perimenopausal Insomnia Symptoms: a Network Meta-analysis [J]. Chinese General Practice, 2023, 26(31): 3963-3974. |
[5] | Climacteric Health Care Branch of Chinese Preventive Medicine Association, Gynecologic Endocrinology and Fertility Professional Committees of China Association for Promotion of Health Science and Technology, Professional Committees of Beijing Association of the Integrating of Traditional and Western Medicine. Chinese Expert Consensus on Clinical Management of Menopause-related Insomnia [J]. Chinese General Practice, 2023, 26(24): 2951-2958. |
[6] | XU Haina, AN Miaomiao, ZHU Yan, WU Chunyan, RAN Limei. Associations of Muscle and Adipose Tissue with Bone Mineral Density in Premenopausal and Postmenopausal Women Undergoing Physical Examination [J]. Chinese General Practice, 2023, 26(21): 2626-2631. |
[7] | LIU Jiamin, DAI Fumin, ZHAO Yasha, HAN Lin. Advances in Falls in the Elderly with Hearing Loss [J]. Chinese General Practice, 2023, 26(13): 1661-1666. |
[8] | GE Jianli, GENG Shasha, CHEN Xin, ZHU Yingqian, SUN Xiaoming, JIANG Hua. Development and Validation of Hearing Loss Screening Software for the Elderly in the Community in the Context of Smart Medicine [J]. Chinese General Practice, 2023, 26(02): 201-209. |
[9] | LI Chao, YANG Yongzhong, WANG Hui, WANG Xuelin, MENG Rui, SI Zhikang, ZHENG Ziwei, CHEN Yuanyu, WU Jianhui. Development and Evaluation of Three Risk Assessment Models for Hearing Loss: a Comparative Study [J]. Chinese General Practice, 2022, 25(35): 4418-4424. |
[10] | GE Jianli, GENG Shasha, CHEN Xin, ZHU Yingqian, SUN Xiaoming, JIANG Hua. Development of the General Practitioner Management of Age-related Hearing Loss System [J]. Chinese General Practice, 2022, 25(34): 4318-4325. |
[11] | Kun YE, Min LEI, Xin XIE, Hui ZHENG, Min CHEN, Shuguang YU. Mechanism of Huangqi Jianzhong Decoction in Treating Diarrhea Predominant Irritable Bowel Syndrome Based on Network Pharmacology and Molecular Docking Technology [J]. Chinese General Practice, 2022, 25(15): 1814-1824. |
[12] |
XIE Zhijia, ZHANG Lei, CHEN Xin, CHANG Tao.
Analysis of Characteristics and Influencing Factors of Hearing Impairment in Patients with Polycystic Ovary Syndrome [J]. Chinese General Practice, 2022, 25(03): 341-345. |
[13] | SUN Kai,ZHU Liguo,WEI Xu,YIN He,LI Qiuyue,QIN Xiaokuan,YANG Bowen1. Chemical Constituents of Zhuangyaotongluo Decoction and Its Mechanism of Action in Delaying the Progression of Lumbar Intervertebral Disc Degeneration: a Study Using UPLC-Q-TOF-MS/MS and Network Pharmacology [J]. Chinese General Practice, 2021, 24(35): 4437-4446. |
[14] | JIAZIREYA·Zaiyinati,XING Shuqing,RENAGULI·Aikebaier,ZHANG Kaidi,ZHANG Yuyuan,XING Bei,WANG Xinling,GUO Yanying. Prevalence and Characteristics of Thyroid Diseases in Peri- and Post-menopausal Women [J]. Chinese General Practice, 2021, 24(3): 310-315. |
[15] | MA Wenjing,Soon-Min Hong,CAO Lanfang. Systemic Lupus Erythematosus Combined with Sensorineural Hearing Loss in Children:a Case Study and Literature Review [J]. Chinese General Practice, 2020, 23(29): 3763-3766. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||